The DOI matches its Crossref record; 16 of the 17 references it cites were found in a registry or an index.
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial
Open accessAbstract
Background Findings of large randomised trials have shown that lowering LDL cholesterol with statins reduces vascular morbidity and mortality rapidly, but limited evidence exists about the long-term efficacy and safety of statin treatment. The aim of the extended follow-up of the Heart Protection Study (HPS) is to assess long-term efficacy and safety of lowering LDL cholesterol with statins, and here we report cause-specific mortality and major morbidity in the in-trial and post-trial periods.Methods 20,536 patients at high risk of vascular and non-vascular outcomes were allocated either 40 mg simvastatin daily or placebo, using minimised randomisation. Mean in-trial follow-up was 5·3 years (SD 1·2), and post-trial follow-up of surviving patients yielded a mean total duration of 11·0 years (SD 0·6). The primary outcome of the long-term follow-up of HPS was first post-randomisation major vascular event, and analysis was by intention to treat. This trial is registered with ISRCTN, number 48489393.Findings During the in-trial period, allocation to simvastatin yielded an average reduction in LDL cholesterol of 1·0 mmol/L and a proportional decrease in major vascular events of 23% (95% CI 19-28; p<0·0001), with significant divergence each year after the first. During the post-trial period (when statin use and lipid concentrations were similar in both groups), no further significant reductions were noted in either major vascular events (risk ratio [RR] 0·95 [0·89-1·02]) or vascular mortality (0·98 [0·90-1·07]). During the combined in-trial and post-trial periods, no significant differences were recorded in cancer incidence at all sites (0·98 [0·92-1·05]) or any particular site, or in mortality attributed to cancer (1·01 [0·92-1·11]) or to non-vascular causes (0·96 [0·89-1·03]).Interpretation More prolonged LDL-lowering statin treatment produces larger absolute reductions in vascular events. Moreover, even after study treatment stopped in HPS, benefits persisted for at least 5 years without any evidence of emerging hazards. These findings provide further support for the prompt initiation and long-term continuation of statin treatment.Funding UK Medical Research Council, British Heart Foundation, Merck & Co, Roche Vitamins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“a timeframe during which a clinical benefit of lipid-lowering therapy would not be expected to emerge 10”
From Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis (2016) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The Heart Protection Study and Cholesterol Treatment Trialists’ Collaborators meta-analyses have demonstrated that statins provide consistent cardiovascular benefits and all-cause mortality reduction for patients [6, 7].”
In the citing paper
“Beneficial effects are retained over longterm follow-up.427”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [427]
In the citing paper
“However, in managing dyslipidemia expressed by hypertriglyceridemia, the non-HDL-C level is more useful than the LDL-C level. This has been reported in a number of studies177–179, 623, 624, 626, 627, 647).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [627]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Report of the Conference on Low Blood Cholesterol: Mortality Associations.
Jacobs, D. R., Blackburn, H., HIGGINS, M. W., REED, D. M., Iso, H., McMillan, G. C., Neaton, J. D., Nelson, J., Potter, J., & Rifkind, B. M. (1992) · Circulation · doi:10.1161/01.cir.86.3.1046 · Cited by 720
Long-term follow-up of the West of Scotland Coronary Prevention Study
Ford, I., Murray, H., Packard, C. J., Shepherd, J., Macfarlane, P. W., & Cobbe, S. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065994 · Cited by 416
Carcinogenicity of Lipid-Lowering Drugs
Newman, T. B. (1996) · JAMA · doi:10.1001/jama.1996.03530250059028 · Cited by 378
Should there be a moratorium on the use of cholesterol lowering drugs?
Smith, G. D., & Pekkanen, J. (1992) · British medical journal · doi:10.1136/bmj.304.6824.431 · Cited by 357
Holdaas, H., Fellström, B., Cole, E., Nyberg, G., OLSSON, A. G., Pedersen, T. R., Madsen, S., Grönhagen‐Riska, C., Neumayer, H. ‐., Maes, B., et al. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01105.x · Cited by 346
Strandberg, T. E., Pyörälà, K., Cook, T. J., Wilhelmsen, L., Færgeman, O., Þorgeirsson, G., Pedersen, T. R., & KJEKSHUS, J. K. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16936-5 · Cited by 329
Cited by
Sorted by citations
Items 201–300 of 377
Lisauskienė, I., Garuolienè, K., & Gulbinovič, J. (2017) · Medicina · doi:10.1016/j.medici.2017.07.004 · Cited by 12
Is antidyslipidemic statin use for cancer prevention a promising drug repositioning approach?
Kobayashi, Y., Banno, K., Kunitomi, H., Nagai, S., Takahashi, T., Anko, M., Iijima, M., Takeda, T., Matoba, Y., Nakamura, K., et al. (2018) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000497 · Cited by 12
Simko, V., & Ginter, E. (2014) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2014_013 · Cited by 11
Tamura, R., Yamanobe, Y., Fujioka, M., Morimoto, Y., Fukumura, M., Nakaya, M., Oishi, Y., Sato, M., Ueda, R., Fujiwara, H., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02376 · Cited by 12
Toth, P. P., Thanassoulis, G., Williams, K., Furberg, C. D., & Sniderman, A. D. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.08.004 · Cited by 11
Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids
Shantha, G., & Robinson, J. G. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.281 · Cited by 11
Itoh, H., Kurihara, I., Miyashita, K., & Tanaka, M. (2017) · Hypertension Research · doi:10.1038/hr.2016.192 · Cited by 11
Ding, C., Hsu, S. H.-J., Wu, Y., & Su, T. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-179 · Cited by 13
Zhao, X.-Q., Phan, B. A. P., Davis, J., Isquith, D. A., Dowdy, A. A., Boltz, S., Neradilek, M. B., Monick, E. A., Brockenbrough, A., Frechette, E. E. H. S., et al. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.06.013 · Cited by 11
Bauters, C., Tricot, O., Lemesle, G., Meurice, T., Hennebert, O., Farnier, M., & Lamblin, N. (2017) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2017.07.007 · Cited by 11
the ASPREE Investigator Group, Agustini, B., Mohebbi, M., Woods, R. L., McNeil, J. J., Nelson, M. R., Shah, R. C., Murray, A. M., Ernst, M. E., Reid, C. M., et al. (2019) · CNS Drugs · doi:10.1007/s40263-019-00633-3 · Cited by 12
Evaluation of lipid metabolism and nutritional status in male goalball players
Gawlik, K., Zwierzchowska, A., & Rosołek, B. (2015) · Journal of Human Kinetics · doi:10.1515/hukin-2015-0100 · Cited by 10
Longitudinal Control of Lipid Levels in Patients With Premature Coronary Artery Disease
Vikulova, D. N., Pinheiro-Muller, D., Rojas‐Fernandez, C. H., Leblond, F., Pimstone, S. N., & Brunham, L. R. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100696 · Cited by 11
Song, X., Zhang, J., & Li, S. (2025) · Electrochemistry Communications · doi:10.1016/j.elecom.2025.107968 · Cited by 10
Bews, H. J., Carlson, J. C., Jha, A., Basu, S., Halayko, A. J., & Wong, C. S. (2014) · Journal of Chromatography B · doi:10.1016/j.jchromb.2013.12.030 · Cited by 10
Saber-Ayad, M. M., Manzoor, S., El-Serafi, A. T., Mahmoud, I., Abusnana, S., & Sulaiman, N. D. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.03.014 · Cited by 10
Kytö, V., Saraste, A., & Tornio, A. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.06.1019 · Cited by 10
Pravastatin for lowering lipids
Adams, S. P., Alaeiilkhchi, N., Tasnim, S., & Wright, J. M. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013673.pub2 · Cited by 9
Goljan, E., Abouelhoda, M., Tahir, A. I., El-Kalioby, M., Meyer, B. F., & Monies, D. (2024) · Human Genomics · doi:10.1186/s40246-024-00594-9 · Cited by 9
The epidemic of nonmelanoma skin cancer and the widespread use of statins
Mascitelli, L., Pezzetta, F., & Goldstein, M. R. (2010) · Dermato-Endocrinology · doi:10.4161/derm.2.1.12128 · Cited by 9
How Important Is Diabetes as a Risk Factor for Cardiovascular and Other Diseases in Older Adults?
Kengne, A. P., & Patel, A. A. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030424 · Cited by 9
Daida, H., Nohara, R., Hata, M., Kaku, K., Kawamori, R., Kishimoto, J., Kurabayashi, M., Masuda, I., Sakuma, I., Yamazaki, T., et al. (2014) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.19109 · Cited by 9
Song, S. H., & Gray, T. A. (2012) · QJM · doi:10.1093/qjmed/hcs113 · Cited by 9
Zachrison, K. S., Levine, D. A., & Hayward, R. A. (2015) · BMJ Evidence-Based Medicine · doi:10.1136/ebmed-2015-110170 · Cited by 9
LDL cholesterol targets – how low to go?
Bulbulia, R. A., & Armitage, J. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283556c1b · Cited by 9
Sever, P. S., Rostamian, S., Whiteley, W. N., Ariti, C. A., Godec, T. R., Gupta, A. K., Mackay, J., Whitehouse, A., & Poulter, N. R. (2025) · Heart · doi:10.1136/heartjnl-2024-325104 · Cited by 8
Long-term statin use and risk of cancers: a target trial emulation study
Xu, W., Chan, L. S., Danaei, G., Lu, Y., & Wan, E. Y. F. (2024) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2024.111425 · Cited by 8
Han, J., Kim, Y., Kang, H. J., Seo, J., Choi, H., Kim, M., Kee, G., Park, S., Ko, S., Jung, H., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-88693-y · Cited by 10
Does the Benefit from Statin Therapy Extend Beyond 5 Years?
Bulbulia, R. A., & Armitage, J. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0297-1 · Cited by 8
The transitioning from trials to extended follow-up studies
Drye, L. T., Casper, A. S., Sternberg, A. L., Holbrook, J. T., Jenkins, G. P., & Meinert, C. L. (2014) · Clinical Trials · doi:10.1177/1740774514547396 · Cited by 8
Statins and myocardial infarction: Type, dose, and administration time: Does it matter?
Παπαγεωργίου, Ν., Zacharia, E. M., Briasoulis, Α., Androulakis, E. S., & Tousoulis, D. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.01.001 · Cited by 8
Lowe, R. N., Marrs, J. C., & Saseen, J. J. (2013) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098612474293 · Cited by 8
Sun, H., Yuan, Y., Wang, P., Cai, R., Xia, W., Huang, R., & Wang, S. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0147-6 · Cited by 8
Statins: Definitive Translational Research
Grundy, S. M. (2014) · Molecular Medicine · doi:10.2119/molmed.2014.00194 · Cited by 8
NHLBI Integrated Pediatric Guidelines: Battle for a Future Free of Cardiovascular Disease
Zachariah, J. P. V., & de Ferranti, S. D. (2012) · Future Cardiology · doi:10.2217/fca.12.72 · Cited by 8
Mihaylova, B., Wu, R., Zhou, J., Williams, C., Schlackow, I., Emberson, J., Reith, C. A., KEECH, A. C., Robson, J. P., Parnell, R., et al. (2024) · Health Technology Assessment · doi:10.3310/kdap7034 · Cited by 8
Cammerer, M. A., Gonçalves, S. C., de Araújo, G. N., Andrades, M. É., Lopes, A. G., & Wainstein, M. V. (2018) · Preventive Nutrition and Food Science · doi:10.3746/pnf.2018.23.2.108 · Cited by 7
Safien, A. M., Ibrahim, N., Subramaniam, P., Shahar, S., Din, N. C., Ismail, A., Singh, D. K. A., & Ludin, A. F. M. (2021) · Gerontology and Geriatric Medicine · doi:10.1177/23337214211025167 · Cited by 9
Böhlke, M., Barcellos, F. C., Santos, I. S., Mielke, G. I., Vargas, M. D. M., & Hallal, P. C. (2022) · Cadernos de Saúde Pública · doi:10.1590/0102-311x00061521 · Cited by 7
Pravastatin-induced rhabdomyolysis and purpura fulminans in a patient with chronic renal failure
Kato, K., Onodera, K., Iwasaki, Y., Matsuda, M., Kawakami, T., Higuchi, M., Kato, K., Kato, Y., Taniguchi, M., & Furukawa, H. (2015) · International Journal of Surgery Case Reports · doi:10.1016/j.ijscr.2015.01.042 · Cited by 7
Wheeler, D. C., & Kasiske, B. L. (2016) · Kidney International · doi:10.1016/j.kint.2016.02.045 · Cited by 7
Sukkar, L., Talbot, B. E. M., Jun, M., Dempsey, E., Walker, R. J., Hooi, L. S., Cass, A., Jardine, M., & Gallagher, M. (2019) · Canadian Journal of Kidney Health and Disease · doi:10.1177/2054358119879896 · Cited by 7
Jaywant, S. V., Singh, A. K., Prabhu, M. S., & Ranjan, R. (2016) · Indian Heart Journal · doi:10.1016/j.ihj.2015.12.016 · Cited by 7
Improving vascular health: are pills the answer?
Smeeth, L. L., & Hemingway, H. (2012) · BMJ · doi:10.1136/bmj.e3802 · Cited by 7
Calabrò, P., Spaccarotella, C., Cesaro, A., Andò, G., Piccolo, R., Rosa, S. D., Zimarino, M., Mancone, M., Gragnano, F., Moscarella, E., et al. (2023) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001440 · Cited by 6
Latest Updates on Lipid Management
Egom, E. E. A., Pharithi, R. B., Hesse, S., Starr, N., Armstrong, R. L., Sulaiman, H. M., Gazdíková, K., Mozos, I. M., Čaprnda, M., Kubatka, P., et al. (2019) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-019-00306-8 · Cited by 5
Kobayashi, D., Mizuno, A., Shimbo, T., Aida, A., & Noto, H. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.03.011 · Cited by 6
Zhou, X., & Yang, Q. (2020) · Journal of Bio-X Research · doi:10.1097/jbr.0000000000000067 · Cited by 6
Kocher, J., Castellucci, T. B., Wen, K., Li, G., Yang, X., Lei, S., Jiang, X., & Yuan, L. (2021) · Pathogens · doi:10.3390/pathogens10070829 · Cited by 6
Ebeling, M., Mühlichen, M., Talbäck, M., Rau, R., Goedel, A., & Klüsener, S. (2023) · Preventive Medicine · doi:10.1016/j.ypmed.2023.107833 · Cited by 6
Improving Cardiovascular Protection: Focus On a Cardiovascular Polypill
Barrios, V., & Escobar, C. (2015) · Future Cardiology · doi:10.2217/fca.15.80 · Cited by 6
Strategies to meet the need for long-term data
Chalmers, J. P., Woodward, M., Borghi, C., Manolis, A. J., & Mancia, G. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000000987 · Cited by 6
Ennezat, P. V., Jemtel, T. H. L., Cosgrove, S., Hallas, J., & Hansen, M. (2018) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2018.1534769 · Cited by 6
Th, A., Go, Y. Y., Lp, L., & Chua, T. (2013) · Singapore Medical Journal · doi:10.11622/smedj.2013008 · Cited by 6
Statins and mortality: the untold story
Kostapanos, M. S., & Elisaf, M. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13202 · Cited by 5
Alazmi, W. M., Fogel, E. L., Watkins, J. L., McHenry, L., Sherman, S., & Lehman, G. A. (2007) · Canadian Journal of Gastroenterology · doi:10.1155/2007/502931 · Cited by 6
The analysis by Manuel and colleagues creates controversy with headlines, not data
Genest, J. J. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041427 · Cited by 6
Satyam, S. M., El-Tanani, M., Patni, M. A., Rehman, A., Irshad, S. M., Raheem, R., Junais, E., John, A. A., Rassal, R. Y., Kumari, R., et al. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05515-3 · Cited by 5
“The Heart Protection Study and Cholesterol Treatment Trialists’ Collaborators meta-analyses have demonstrated that statins provide consistent cardiovascular benefits and all-cause mortality reduction for patients [6, 7].”
Okere, A. N., & Serra, C. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1621 · Cited by 5
Al-Siyabi, K. (2010) · Oman Medical Journal · doi:10.5001/omj.2010.79 · Cited by 5
Niveles óptimos de colesterol en los pacientes con dislipemia. Revisión sistemática de la evidencia
Escobar, C., Barrios, V., & de Isla, L. P. (2017) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2017.08.006 · Cited by 5
Sasaki, K., Watanabe, Y., Kozuma, K., Kataoka, A., Hioki, H., Nagura, F., Yashima, F., Shirai, S., Tada, N., Yamawaki, M., et al. (2021) · Heart and Vessels · doi:10.1007/s00380-021-01873-4 · Cited by 5
Statinintoleranz und statinassoziierte Muskelschmerzen
Stürzebecher, P. E., Schumann, F., Kassner, U., & Laufs, U. (2022) · Herz · doi:10.1007/s00059-022-05114-w · Cited by 5
INCREASING SOLUTION IN THE DRUG SIMVASTATIN WITH SOLID DISPERSION TECHNIQUE USING POLYMER SOLUPLUS
Sopyan, I., RIYALDI, M. R., Mita, S. R., & HARIONO, M. (2023) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2023v15i4.48293 · Cited by 5
Luo, Q., Chen, J., Su, Y., Wu, P., Wang, J., Fang, Z., & Luo, F. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01910-3 · Cited by 5
Tomasik, T., Windak, A., Seifert, B., Kersnik, J., Kijowska, V., & Dubas‐Jakóbczyk, K. (2012) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248412471196 · Cited by 5
Treatment with statins improves long-term survival in individuals with carotid artery stenosis
Wörlund, S. M., Kurz, M. W., Hegland, Ø., Brønnick, K., Munk, P. S., & Larsen, J. P. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.01.198 · Cited by 5
Ramjeeth, A., Butkow, N., Raal, F. J., & Maholwana-Mokgatlhe, M. (2008) · Europe PMC (PubMed Central) · Cited by 5
Otake, H., Tanimura, K., Sugizaki, Y., Toba, T., Kawamori, H., Shinke, T., & Hirata, K. (2019) · Circulation Reports · doi:10.1253/circrep.cj-18-0021 · Cited by 5
Han, B. H., Weinberger, Y., & Sutin, D. G. (2014) · Journal of General Internal Medicine · doi:10.1007/s11606-014-2959-x · Cited by 5
Ennezat, P. V., Alavi, Z., Jemtel, T. H. L., & Hansen, M. R. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001215 · Cited by 6
Lipid-modifying and antiatherosclerotic drugs
Gotto, A. M., & Opie, L. H. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-3322-4.00019-3 · Cited by 5
Shibahashi, E., Jujo, K., Mizobuchi, K., Nakao, M., Uchigata, Y., & Yamaguchi, J. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.09.018 · Cited by 6
Simvastatin for lowering lipids
Adams, S. P., Alaeiilkhchi, N., & Wright, J. M. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014857 · Cited by 5
Chen, L., Chen, Q., Zhong, J., Ye, Z., Ye, M., Yan, Y., Chen, L., & Luo, Y. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.679599 · Cited by 5
Might money spent on statins be better spent?
Jenkins, A. J. (2003) · BMJ · doi:10.1136/bmj.327.7420.933-b · Cited by 5
Rossi, R., Nouri, A., Akman, Z., Nezhad, S. A., Damluji, A. A., & Nanna, M. G. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02329-1 · Cited by 5
Muhammad, R. N., Aborehab, N. M., Aly, S. H., Nasr, N. N., Hindam, M. O., Mustafa, A. M., Faheem, S. A., Fawzy, M. H., Fetoh, M. E. A., El‐Dessouki, A. M., et al. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-02069-2 · Cited by 5
Chowdhury, F. A., Baker, S. M. E. A., Islam, M. S., Nahid, N. A., Al-Mamun, M. M. A., Islam, M. R., Apu, M. N. H., Nahar, Z., Ahmed, M. U., & Hasnat, A. (2019) · Drugs & Therapy Perspectives · doi:10.1007/s40267-019-00677-x · Cited by 4
Zhu, L., Bell, K., Nayak, A., & Hayen, A. D. (2020) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2020.11.008 · Cited by 4
McMillin, G. A., Wadelius, M., & Pratt, V. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-816061-9.00011-4 · Cited by 4
Optimal search strategies for identifying moderators and predictors of treatment effects in PubMed
Tummers, M., van Hoorn, R., Levering, C., Booth, A., van der Wilt, G. J., & Kievit, W. (2018) · Health Information & Libraries Journal · doi:10.1111/hir.12230 · Cited by 5
Yoshida, H., Yanai, H., Shoda, T., Furutani, N., Sato, N., & Tada, N. (2005) · Current Therapeutic Research · doi:10.1016/j.curtheres.2005.12.008 · Cited by 4
Prolonged and Pronounced Low-Density Lipoprotein Cholesterol Lowering: The Gift That Keeps Giving
Shapiro, M. D. (2022) · Circulation · doi:10.1161/circulationaha.122.061727 · Cited by 4
Kafol, J., Fras, Z., Novaković, M., Sperling, L. S., Cevc, M., Krevel, B., Kafol, L., Kelenc, A., Kepic, K., Vrbinc, K. N., et al. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02897-3 · Cited by 3
Update and validation of the lifetime cardiovascular risk in Spain: IBERLIFERISK2
Brotons, C., Moral-Peláez, I., Vicuña, J., Ameixeiras, C., Fernández-Lavandera, C., & Sánchez-Chaparro, M. Á. (2023) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2023.05.008 · Cited by 3
Statins for primary prevention in physically active individuals: Do the risks outweigh the benefits?
Mansi, I. A., English, J. L., Morris, M. J., Zhang, S., Mortensen, E. M., & Halm, E. A. (2017) · Journal of science and medicine in sport · doi:10.1016/j.jsams.2016.12.075 · Cited by 3
Expert group from the Spanish Arteriosclerosis Society, Pedro‐Botet, J., López‐Miranda, J., Badimón, L., Civeira, F., Guijarro, C., Millán, J., Mostaza, J. M., Pintó, X., Valdivielso, P., et al. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00376-y · Cited by 3
Anabolic Effects of a Novel Simvastatin Derivative on Treating Rat Bone Defects
Lee, T., Chen, H., Tai, I., Kao, L.-T., Hung, M.-H., Chen, C., Fu, Y., Wang, Y., Kao, C.-M., Chang, J., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10081915 · Cited by 3
Liu, L., Brokenshire, B., Davies, D., & Harrison, J. (2024) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-024-01740-y · Cited by 4
Secondary stroke prevention: misguided by guidelines?
Vanstreels, L., Molenberghs, G., & Voigt, J. (2012) · Acta cardiologica. Supplementum · doi:10.1080/ac.67.4.2170684 · Cited by 3
Role of coronary physiology in the contemporary management of coronary artery disease
Ruparelia, N. (2015) · World Journal of Clinical Cases · doi:10.12998/wjcc.v3.i2.148 · Cited by 3
Toth, P. P. (2012) · Yearbook of Endocrinology · doi:10.1016/j.yend.2012.05.025 · Cited by 3
Zhang, H. (2013) · World Journal of Meta-Analysis · doi:10.13105/wjma.v1.i3.130 · Cited by 3
Craveiro, N. S., Lopes, B. S., Tomás, L., Almeida, S. F., Palma, H., Afreixo, V. M. A., & Matos, L. C. (2019) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4895 · Cited by 3
Tough targets are necessary in effective diabetes care
Chowdhury, T. A., & Lasker, S. S. (2002) · BMJ · doi:10.1136/bmj.325.7367.775 · Cited by 3
Luther, J., & Chan, A. T. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch78 · Cited by 3
Ference, B. A., Ference, T. B., Catapano, A. L., Nicholls, S. J., & Ray, K. K. (2024) · medRxiv · doi:10.1101/2024.06.30.24309740 · Cited by 3
Wuttikul, C., Kaew-umpa, P., Kosumphant, A., Jitranon, P., Kunuphathum, R., & Kaewbut, P. (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.2.286 · Cited by 2
Soverow, J. E., & Watson, K. E. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0432-2 · Cited by 2
Metadata
- Authors
- Heart Protection Study Collaborative Group
- Corresponding author
- Heart Protection Study Collaborative Group
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2011-12
- Volume
- 378
- Issue
- 9808
- Pages
- 2013-2020
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC3242163
- OpenAlex
- W2133184701
- Cited by
- 373
- References
- 17
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 15 · 2023: 17 · 2022: 14 · 2021: 13 · 2020: 14 · 2019: 20 · 2018: 25 · 2017: 17 · 2016: 28 · 2015: 29 · 2014: 27 · 2013: 41 · 2012: 38
- FWCI
- 38.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Funders
- British Heart Foundation
- Medical Research Council (MC_EX_G0801669)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- statin therapy, simvastatin, LDL cholesterol lowering, long-term efficacy, vascular death, major vascular events, cancer incidence, post-trial follow-up, Heart Protection Study, high-risk patients, statin safety, lipid-lowering therapy, secondary prevention of cardiovascular disease, long-term follow-up, cardiovascular risk reduction
- MeSH terms
- Adult, Aged, Aged, 80 and over, Cholesterol, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Myocardial Revascularization, Neoplasms, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
